Open AccessSurvival Benefit of Intravenous Busulfan (120 mg/M2) and Fludarabine Myeloablative Regimen for Treatment of Myeloid Malignancies
Author(s) -
Pimjai Niparuck
Publication year - 2016
Publication title -
journal of stem cell research and therapy
Language(s) - English
Resource type - Journals
ISSN - 2157-7633
DOI - 10.4172/2157-7633.1000338
Subject(s) - fludarabine , busulfan , medicine , regimen , oncology , myeloid , transplantation , surgery , chemotherapy , hematopoietic stem cell transplantation , cyclophosphamide